Picture of Zevra Therapeutics logo

ZVRA — Zevra Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Zevra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Zevra Therapeutics Inc  ZVRA.OQ  reported a quarterly
adjusted
loss of 69 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -40 cents.  The mean expectation of eight analysts for
the quarter was for a loss of 42 cents per share. Wall Street
expected results to range from -50 cents to -36 cents per share.
    * Revenue rose 27.6% to $3.70 million from a year ago;
analysts
expected $4.87 million. 
    * Zevra Therapeutics Inc's reported EPS for the quarter was
a loss
of 69 cents​.
    * The company reported a quarterly loss of $33.23 million.
    * Zevra Therapeutics Inc shares had risen by 29.1% this
quarter and gained 36.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Zevra
Therapeutics Inc is $20.50 
This summary was machine generated from LSEG data November 12 at
11:28 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.42          -0.69          Missed
 Jun. 30 2024      -0.43          -0.48          Missed
 Mar. 31 2024      -0.48          -0.40          Beat
 Dec. 31 2023      -0.27          -0.40          Missed

Recent news on Zevra Therapeutics

See all news